A Review of Hepatitis C Virus (HCV) and the Current Management of Genotype 1 Chronic HCV Infection
The Nigerian Health Journal
; 12(4): 90-96, 2012.
Article
em En
| AIM
| ID: biblio-1272837
Biblioteca responsável:
CG1.1
ABSTRACT
Chronic Hepatitis C virus (HCV) is the primary cause of cirrhosis; hepatocellular carcinoma (HCC); and end- stage liver disease. The addition of protease inhibitor with peginterferon alfa and ribavirin (triple therapy) for genotype 1 infected patients; are the current standard of care.Method:
Data was sourced from available journals and internet based search using pubmed; medline and google search.Results:
successful Treatment of Genotype 1 HCV infected patients with protease inhibitor based triple therapy has improved sustained virologic response (SVR) rates and treatment induced clearance of HCV infection.Conclusion:
significant progress in the management of chronic hepatitis C genotype 1 with the introduction of protease inhibitor (PI) in 2011 with peginterferon and ribavirin has optimized sustained virologic response (SVR)
Buscar no Google
Assunto principal:
Inibidores de Proteases
/
Ribavirina
/
Viroses
/
Hepacivirus
/
Gerenciamento Clínico
Idioma:
En
Revista:
The Nigerian Health Journal
Ano de publicação:
2012
Tipo de documento:
Article